Sutro Biopharma, Inc.
STROHealthcare|Biotechnology|US
$9.62
+0.42 (+4.57%)
Cash / Share
$9.92
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07227168 A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC | P1 | Recruiting | 200 | Open-label | STRO-004, Pembrolizumab |
| NCT07807345 Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer | P1 | Recruiting | 285 | Open-label | STRO-006, Pembrolizumab |
| NCT05870748 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | Ovarian Cancer, Epithelial Ovarian Cancer | P2P3 | Terminated | 600 | RCT, Open-label | Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan |
| NCT06238687 A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors | Neoplasm Malignant | P1P2 | Completed | 19 | Open-label | STRO-002 |
| NCT06555263 Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | Lung Cancer, Lung Cancer Metastatic | P2 | Withdrawn | — | Open-label | Luveltamab tazevibulin |
| NCT06679582 Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | Acute Myeloid Leukemia (AML) | P1P2 | Terminated | 1 | RCT, Open-label | Luveltamab tazevibulin |
| NCT05200364 A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | Ovarian Cancer, Ovarian Carcinoma | P1 | Terminated | 58 | Open-label | STRO-002, Bevacizumab |
| NCT03748186 Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Ovarian Cancer, Ovarian Carcinoma | P1 | Completed | 136 | Open-label | STRO-002 |
| NCT03424603 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | B-cell Lymphoma, Non Hodgkin Lymphoma | P1 | Completed | 70 | Open-label | STRO-001 |